Bank of America Announces Accelerator Program that Provides Economic Opportunities to Entrepreneurs from Underrepresented Communities

Bank of America is pleased to officially launch its impact accelerator program named Bank of America Breakthrough Lab with the call for applications for the September 2023 cohort. The six-month program provides tailored mentorship, digital expertise, networking with industry experts…

Read MoreBank of America Announces Accelerator Program that Provides Economic Opportunities to Entrepreneurs from Underrepresented Communities

Warren Buffett and J.P. Morgan Have One Thing in Common: They Both Like These 2 Stocks

When the legendary investor Warren Buffett makes a move, Wall Street pays attention. Known as the ‘Oracle of Omaha’ and the mastermind behind Berkshire Hathaway, Buffett has amassed a fortune of over $100 billion throughout his career. Buffett’s preferred investing style has…

Read MoreWarren Buffett and J.P. Morgan Have One Thing in Common: They Both Like These 2 Stocks

Simon Property Group Stock (NYSE:SPG): 7% Yield, and Dividends Keep Rising

Simon Property Group’s Fiscal Q1-2023 results showcased ongoing financial and operational enhancements, including a dividend increase. With the potential for more dividend hikes and shares appearing undervalued, SPG stock could present a compelling opportunity. Simon Property Group (NYSE:SPG) stock is…

Read MoreSimon Property Group Stock (NYSE:SPG): 7% Yield, and Dividends Keep Rising

Investor’s Head of Corporate Communication & Sustainability Viveka Hirdman-Ryrberg steps down

Viveka Hirdman-Ryrberg, age 60, has decided to step down after close to fiveyears at Investor and more than 30 years within the Wallenberg sphere.“Viveka has been instrumental in setting and driving our sustainability strategy aswell as gearing up our communication…

Read MoreInvestor’s Head of Corporate Communication & Sustainability Viveka Hirdman-Ryrberg steps down

Investor supports Sobi’s tender offer for CTI BioPharma and undertakes to subscribe for its pro rata share in Sobi’s rights issue

Sobi has today communicated its offer to acquire CTI BioPharma (CTI), a US listed company within hematology, for USD 9.10 per share, equivalent to an enterprise value of USD 1.7bn and to carry out a rights issue with preferential rights…

Read MoreInvestor supports Sobi’s tender offer for CTI BioPharma and undertakes to subscribe for its pro rata share in Sobi’s rights issue